Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 7c, Revenues Miss

Eagle Pharmaceuticals (EGRX) PT Lowered to $64 at RBC Capital

RBC Capital analyst Randall Stanicky lowered the price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $64.00 (from $84.00) while maintaining an Outperform rating.

Stanicky said results place a spotlight on recent pipeline setbacks and outlook.

Piper Jaffray Downgrades Eagle Pharmaceuticals (EGRX) to Neutral

Piper Jaffray analyst David Amsellem downgraded Eagle Pharmaceuticals (NASDAQ: EGRX) from Overweight to Neutral with a price target of $54.00 (from $82.00).

For an analyst ratings summary and ratings history on Eagle Pharmaceuticals click here. For more ratings news on Eagle Pharmaceuticals click here.

Shares of Eagle Pharmaceuticals closed at $47.50 yesterday.

Eagle Pharmaceuticals (EGRX) Reports Prelim. 3Q EPS Above Consenus, Prelim. 3Q Revenues Below Consensus

Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) today provided preliminary financial results and announced that its Board of Directors has approved a new stock repurchase program providing for the repurchase of up to an aggregate of $150 million of Eagles common stock, consisting of (i) up to $50 million in repurchases pursuant to an accelerated... More

Eagle Pharmaceuticals (EGRX) Initiates $50M Accelerated Share Buyback as Part of New $150M Share Buyback Authorization

Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) today provided preliminary financial results and announced that its Board of Directors has approved a new stock repurchase program providing for the repurchase of up to an aggregate of $150 million of Eagles common stock, consisting of (i) up to $50 million in repurchases pursuant to an accelerated share repurchase (ASR) transaction with JPMorgan Chase Bank, National Association (JP Morgan) and (ii) up to $100 million in additional repurchases. This reflects the Company's conviction in its business strategy.

The specific... More